
S&P TEST

SWOT & PESTLE.com

BIOMARIN PHARMACEUTICAL SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email support@swotandpestle.com.

Company Name : Biomarin Pharmaceutical

Company Sector : Pharmaceutical

Operating Geography : United States, North America, Global

About the Company :

BioMarin Pharmaceutical Inc. or BioMarin as it is popularly known is a multinational pharmaceutical for various diseases and medical conditions. This American biotechnology company, headquartered in San Rafael, California selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. Their offering basket comprises of several commercial products and multiple clinical and pre-clinical product candidates for the treatment of various diseases. The Company continues to invest in their clinical and pre-clinical product pipeline by committing significant resources to research and development initiatives and business development opportunities within their orbit of scientific, manufacturing and technical expertise.

BioMarin's therapy portfolio is built of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. As of early 2022, BioMarin had 3,045 full-time employees.

BioMarin's USP lies in developing and commercializing innovative therapies for people with serious and life-threatening rare diseases and medical conditions. Biomarin's mission statement reads "to bring new treatments to market that will make a big impact on small patient populations."

Revenue :

\$1,846.2 million – FY ending 31st Dec 2021

\$1,860.4 million – FY ending 31st Dec 2020

SWOT Analysis :

The SWOT Analysis for Biomarin Pharmaceutical is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> 1. World leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes 2. Bringing speedy innovative therapies to meet critical patient needs 3. Diversified rare disease player 4. Bellwether in several therapeutic treatments for life-threatening conditions 	<ul style="list-style-type: none"> 1. Scaling indebtedness weighing on company profits 2. Highly priced products to recover investment costs 3. Clouds of uncertainty looming large on BioMarin's prospects
Opportunities	Threats
<ul style="list-style-type: none"> 1. Revolutionize the Hemophilia treatment market 2. Focused on advancing its position in PKU indication 3. Reorganizational efforts to focus on core strength in genetic discovery 	<ul style="list-style-type: none"> 1. Intense competition in biopharmaceutical industry 2. Challenges with patents and proprietary rights protection 3. Increased regulatory enforcements related to specialty drug pricing practices 4. Risk of rejection by regulatory authorities outside the U.S. and the EU 5. Changes in methods of treatment of disease could reduce demand for BioMarin's products and adversely affect revenues

PESTLE Analysis :

The PESTLE Analysis for Biomarin Pharmaceutical is given below:

<p style="text-align: center;">Political</p> <ol style="list-style-type: none"> 1. Biopharma companies pledge to stop investments in Russia in the wake of Russia-Ukraine war 2. Drugmakers dramatically shot lobbying spends during Trump administration 	<p style="text-align: center;">Economical</p> <ol style="list-style-type: none"> 1. Impact of COVID-19 on pharmaceuticals
<p style="text-align: center;">Social</p> <ol style="list-style-type: none"> 1. Access to generic medicines worldwide 2. Increasing focus on healthcare for women 	<p style="text-align: center;">Technological</p> <ol style="list-style-type: none"> 1. Leveraging AI to identify drug candidates 2. Collaboration with significant pharmaceuticals to enhance R&D
<p style="text-align: center;">Legal</p> <ol style="list-style-type: none"> 1. Lawsuits against the employees for stealing trade secrets 2. Pricing is approved by cost watchdog ICER 3. Following stringent regulations for AE and SSE 	<p style="text-align: center;">Environmental</p> <ol style="list-style-type: none"> 1. Achieving carbon neutrality by 2045

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Biomarin Pharmaceutical** SWOT & PESTLE Analysis is a paid report at **12.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:
support@swotandpestle.com